ROCKET PHARMACEUTICALS, INC.

RCKTW

N/A

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 2, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

1 upcoming, 0 past

🎯PDUFANext

FDA PDUFA Date RP-L201 (priority)

4/2/2026

For Leukocyte Adhesion Deficiency Type I (LAD-I). BLA filing. Extracted from SEC filing: 8-K

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

RP-L102

Phase 2

Fanconi Anemia Complementation Group A

Drug Name	Phase	Indication	Designations
RP-L102	Phase 2	Fanconi Anemia Complementation Group A	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

RCKTW News